{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:10:46Z","timestamp":1787019046319,"version":"build-2736575974"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Background: Data regarding safety of nonselective \u03b2-blockers (NSBBs) in patients with end-stage cirrhosis are conflicting, making it difficult for practitioners to justify if benefits outweigh the risks. Objective: Evaluate the effect of NSBB use on mortality in patients with end-stage cirrhosis. Methods: We performed a dual-center retrospective study of patients who received octreotide for a variceal bleed. Patients were stratified into 2 groups based on whether or not a NSBB was prescribed at hospital discharge. The primary outcome was 24-month mortality. Multivariable logistic regression, with 24-month mortality as the dependent variable, was performed to identify independent risk factors for the primary outcome. Results: 255 patients met inclusion criteria; 24-month mortality was 32.8%. The NSBB and no-NSBB groups had similar mortality rates at 24 months (32.0% vs 38.5%, P = 0.51). Mortality at 3 months (11.6% vs 23.3%, P = 0.08) and 12 months (22.2% vs 30.0%, P = 0.36) were similar, and there were no differences in rate of variceal bleeding (22.7% vs 13.3%, P = 0.34) or cirrhosis-related cause of death (20.4% vs 23.3%, P = 0.81). In the multivariable model, age, model for end-stage liver disease with sodium and hepatocellular carcinoma were independent risk factors for 24-month mortality. NSBB therapy had no effect on 24-month mortality (adjusted odds ratio = 1.05; 95% CI = 0.32 to 3.40). Conclusion and Relevance: In patients with end-stage cirrhosis, use of NSBBs did not affect 24-month mortality. More research is needed to determine when, and if, NSBBs should be discontinued in end-stage cirrhosis.<\/jats:p>","DOI":"10.1177\/1060028019886529","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T11:55:13Z","timestamp":1573214113000},"page":"322-330","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Nonselective \u03b2-Blockers on Mortality in Patients With End-Stage Cirrhosis"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-3166","authenticated-orcid":false,"given":"Jenna L.","family":"Snoga","sequence":"first","affiliation":[{"name":"University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"},{"name":"South Texas Veterans Healthcare System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Lusk","sequence":"additional","affiliation":[{"name":"University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"},{"name":"UT Health San Antonio, TX, USA"},{"name":"University Health System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell T.","family":"Attridge","sequence":"additional","affiliation":[{"name":"University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"},{"name":"South Texas Veterans Healthcare System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Attridge","sequence":"additional","affiliation":[{"name":"University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA"},{"name":"UT Health San Antonio, TX, USA"},{"name":"University Health System, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"bibr1-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"bibr2-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000208"},{"key":"bibr3-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.021"},{"key":"bibr4-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.1997.v25.pm0008985266"},{"key":"bibr5-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21907"},{"key":"bibr6-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28906"},{"key":"bibr7-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"bibr8-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23775"},{"key":"bibr9-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.034"},{"key":"bibr10-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.005"},{"key":"bibr11-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28352"},{"key":"bibr12-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306502"},{"key":"bibr13-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301348"},{"key":"bibr14-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1504367"},{"key":"bibr15-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22853"},{"key":"bibr16-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.029"},{"key":"bibr17-1060028019886529","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.948053"},{"key":"bibr18-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26676"},{"key":"bibr19-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14366"},{"key":"bibr20-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.01.012"},{"key":"bibr21-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90441-6"},{"key":"bibr22-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.180570"},{"key":"bibr23-1060028019886529","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.031"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019886529","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019886529","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019886529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:15Z","timestamp":1777374915000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019886529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1177\/1060028019886529"],"URL":"https:\/\/doi.org\/10.1177\/1060028019886529","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]}}}